Phase 1 Study of Zoledronic Acid in Sickle Cell Disease
- Registration Number
- NCT00639392
- Lead Sponsor
- Virginia Commonwealth University
- Brief Summary
The long-term goal of this study is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. The goal of this study is to learn about the safety of Zoledronic Acid in persons with sickle cell disease who experience chronic pain requiring medical treatment or use of narcotics.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- 18 years and older
- Male or female with sickle cell disease
- Pain related to sickle cell disease Patient history of health services utilization for acute SCD-related pain Patient history of use of narcotic analgesics for pain control within the past 6 months
- Able to tolerate hydration with 500 mL D51/2 NS prior to Zoledronic Acid or placebo
Exclusion Criteria
- Calculated creatinine clearance less than 60 mL/min
- Current active dental problems
- Recent (within 6 weeks) or planned dental or jaw surgery (e.g., extraction,implants)
- History of cirrhosis or chronic symptomatic liver disease; acute liver disease
- History of aspirin-induced asthma
- History of allergy to zoledronic acid or similar chemical-entities
- Pregnant or nursing
- No prior bisphosphonate use
- Receipt of an investigational drug within 30 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Placebo Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3. 1 Zoledronic Acid Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive Zolendronic Acid are 2 out of 3.
- Primary Outcome Measures
Name Time Method The long-term goal of this project is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. Within 2 weeks of study drug administration and then every month for approximately 1 year
- Secondary Outcome Measures
Name Time Method The specific purposes of this study are to learn if Zoledronic Acid has serious side effects for subjects with sickle cell disease and to study the effects of Zoledronic acid in subjects with sickle cell disease. Two weeks after study drug administration and then every month for approximately 1 year
Trial Locations
- Locations (1)
Virginia Commonwealth University
🇺🇸Richmond, Virginia, United States